ZBIO: Zenas Bio Price Target Chart
Historical price action on the GURU.Markets platform shows quotes for Zenas Biopharma Inc (ZBIO), whose profits are based on the development of advanced antibodies for the therapy of inflammatory processes. The business faces stringent FDA oversight and colossal research costs, which limit the entry of new players. Zenas Biopharma Inc (ZBIO) is currently focusing on attracting major investors to support clinical trials, while the current indicator stands at 47.98.
Analytical breakdowns for Zenas Biopharma, Inc. (ZBIO)
- share price and expert price forecast:
- market capitalization information:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Zenas Biopharma Inc|ZBIO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Zenas Corp|ZBIO - Company Aggregate Debts|Debts to Book Capitalization Zenas Biopharma, Inc.|ZBIO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Zenas Biopharma|Quick Liquidity Indicator zenasbio.com
- net income and valuation ratios data:
ZBIO - Net Profit|Projected Future Earnings Zenas Biopharma Inc|ZBIO - Price to Earnings Ratio|Future Price to Earnings Multiple Zenas Bio|ZBIO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma, Inc.|ZBIO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Zenas Biopharma|ZBIO - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zenasbio.com|ZBIO - Net earnings per share growth this year|Earnings growth forecast for next year Zenas Biopharma Inc
General company analysis:ZBIO zenasbio.com
The consensus forecast reflects the weighted average fair value assessment of the asset, based on the aggregate calculations of leading investment banks. The trend in the expected consensus share value demonstrates market confidence in future cash flows. This indicator is calculated by aggregating analysts' price targets, filtering out short-term noise. For Zenas Biopharma Inc (ZBIO), a stable target confirms the high value of its unique bispecific antibodies. Patent protection of developments minimizes the risks of downward valuation revisions.
Competitors of Zenas Biopharma Inc
ARGX: Forecast Levels Chart|Analyst Consensus Forecast BNTX (BioNTech)|Abivax SA - Price Target Chart|ADMA Bio - Analyst Consensus Forecast|Analyst Median Target Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price Target Chart|Average Forecast Price kiniksa.com (KNSA)|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast IMNM (Immunome Corp)|Analyst Median Target Gossamer Bio Corp. (GOSS)|KALV - Price Target Chart|septerna.com (SEPN) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS: Consensus Target|Forecast Levels Chart KYTX|TLSA: Analyst Consensus Forecast|Average Forecast Price cabalettabio.com (CABA)|Price Target Chart Ventyx Biosciences, Inc.|Broker Consensus Forecast THTX (Theratechnologies, Inc.)|Analyst Consensus Forecast AVTX|Analyst Consensus Forecast Eledon Pharmaceuticals, Inc (ELDN)|Price Target Chart Agenus AGEN|Analyst Median Target climbbio.com (CLYM)|ZURA: Consensus Target|Fair Value Consensus ATYR (aTyr Pharma Inc)|ADAG: Analyst Consensus Forecast|IMA (Ikena Oncology) - Price Target Chart|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Equillium Bio (EQ) - Analyst Median Target|Price Target Chart Connect Biopharma (CNTB)|IMUX - Average Forecast Price|Price Target Chart Atara Bio ATRA|IFRX (InflaRx NV) - Forecast Levels Chart|X4 Pharmaceuticals - Analyst Consensus Forecast|Fair Value Consensus ACET (Adicet Bio)|CELU: Analyst Consensus Forecast|INmune Bio Inc (INMB) - Analyst Consensus Forecast|Price Target Chart Barinthus Bio|KZR: Fair Value Consensus|Price Target Chart SAB Biotherapeutics (SABS)|Consensus Target akaritx.com AKTX|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Analyst Consensus Forecast Q32 Bio Inc QTTB|GOVX: Consensus Target|Fair Value Consensus EDSA (Edesa Biotech Corp)|IBIO: Analyst Consensus Forecast|CARM - Analyst Median Target|Price Target Chart XTL Biopharmaceuticals Ltd.|Broker Consensus Forecast BOLT (Bolt Bio)|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|AIM ImmunoTech - Consensus Target|ADTX (Aditxt Inc.) - Forecast Levels Chart|GRI Bio - Analyst Consensus Forecast|XRTX: Price Target Chart|HIND: Analyst Consensus Forecast|REVB - Analyst Median Target|Price Target Chart Indaptus Therapeutics|Average Forecast Price scinai.com SCNI|Price Target Chart CalciMedica, Inc. (CALI)|AFMD: Forecast Levels Chart|Analyst Consensus Forecast ALLK (Allakos)|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|TC BioPharm (Holdings) Plc - Fair Value Consensus|Price Target Chart Third Harmonic Bio, Inc
